breast cancer pathology report

Release time ：Dec-19,2024

The breast cancer pathology report indicates a tumor measuring 2 centimeters in size, classified as T2 stage. The histological subtype is invasive ductal carcinoma, with a grade of 2. Both estrogen receptor (ER) and progesterone receptor (PR) are positive, while human epidermal growth factor receptor 2 (HER2) is negative. Lymph node assessment reveals involvement of two lymph nodes.

Based on this report, the patient's breast cancer is categorized as early to intermediate stage. T2 stage implies a tumor size ranging from 2 to 5 centimeters, and a grade 2 classification suggests a moderate rate of cancer cell growth and spread. The positivity for ER and PR indicates that this breast cancer subtype is responsive to hormonal therapy, offering the patient a broader range of treatment options. The negative HER2 status rules out the use of specific targeted therapies. The presence of involved lymph nodes suggests that the cancer cells may have begun to disseminate through the lymphatic system, potentially influencing the selection of treatment protocols and prognostic assessments.

It is advised that the patient promptly consults with a specialized healthcare team to discuss the treatment plan. The treatment may involve surgical excision of the tumor, followed by consideration of adjuvant therapies such as radiation, chemotherapy, or hormonal therapy, depending on the specific circumstances. The patient should adhere to the physician's recommendations, engage in regular follow-ups and monitoring to ensure timely adjustments to the treatment plan and to evaluate the therapeutic outcomes. Additionally, the patient should maintain healthy lifestyle practices, including a balanced diet, regular physical activity, and abstaining from smoking, to support the treatment process and enhance the quality of life.